|
| The (D2OL)™ platform was initially
created by Sengent, Inc. to improve the cost and overall efficiency
of evaluating potential drug candidates necessary to address
general health concerns. Thanks to overwhelming public contribution,
(D2OL)™ is now a standalone effort fully focused on discovering
novel drug leads for biological targets. |
|
|
|
| Despite significant advances in the
availability of chemical compounds, current scientific processes
and methods to date have proved slow, costly and unreliable.
Leveraging Sengent CommunityOS™ technology, a network
of collaborating Scientists, and an open collaboration model,
(D2OL)™ represents the authoritative platform providing
the depth, sophistication and flexibility necessary to accelerate
meaningful progress in structure based drug design. |
|
|
|
| (D2OL)™ uses the idle time on your
personal computer to help find a cure for emerging pathogens.
Simply stated, (D2OL)™ is a software program that is
downloaded to your computer and given a biological target and drug
candidates to evaluate.
(D2OL)™ technology allows drug candidates
to be fit to target disease molecules like fitting a key
to a lock. As a user, no intervention is required and the
software will test candidates as long as it is running.
You do not need to be connected to the internet for it to
work.
Read more about the science of Large
Scale Virtual Screening (PDF Format).
this page last reviewed
April 15, 2009
|
|
|
|
